The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation

Thyroid

Volumn 22, Issue 2, 2012, Pages 113-116

  Rosario, Pedro Weslley ^a,b   Mineiro Filho, Augusto Flávio Campos ^a   Lacerda, Rafela Xavier ^a   Dos Santos, Davi Alves ^a   Calsolari, Maria Regina ^b  

^a Postgraduate Program   (Brazil)

^b Endocrinology Service   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ABLATION THERAPY; ADOLESCENT; ADULT; AGED; BONE METASTASIS; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVE IODINE ABLATION; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84856623642     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0020     Document Type: Review

References (24)

1. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178. (Pubitemid 32268810)
2. Rosario PW, Borges MA, Costa GB, Rezende LL, Padrão EL, Barroso AL, Purisch S 2007 Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131. Arq Bras Endocrinol Metab 51:99-103.
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
5. Pitoia F, Ward L, Wohllk N, Friguglietti C, Tomimori E, Gauna A, Camargo R, Vaisman M, Harach R, Munizaga F, Corigliano S, Pretell E, Niepomniszcze H 2009 Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metab 53:884-887.
6. Rosario PW, Borges MA, Fagundes TA, Franco AC, Purisch S 2005 Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 62:121-125. (Pubitemid 40203904)
7. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441. (Pubitemid 36623351)
8. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673. (Pubitemid 37034512)
9. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87:3242-3247. (Pubitemid 34816372)
10. Rosario PW, Borges MA, Alves MF, Purisch S, Padrão EL, Rezende LL, Barroso AL 2006 Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy. Arq Bras Endocrinol Metab 50:909-913. (Pubitemid 44973525)
11. Spencer CA, Takeuchi M, Kazaroxyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121-1127. (Pubitemid 28496379)
12. Rosario PW, Maia FF, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S 2004 Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. Arq Bras Endocrinol Metab 48:487-492.
13. Mazzaferri EL 2005 Empirically treating high serum thyro-globulin levels. J Nucl Med 46:1079-1088. (Pubitemid 43741068)
14. Wittekind C, Compton CC, Greene FL, Sobin LH 2002 TNM residual tumor classification revisited. Cancer 94:2511-2516. (Pubitemid 34457134)
15. Rosario PW, Faria S, Bicalho L, Gatti Alves MF, Borges MA, Purisch S, Padrao EL, Rezende LL, Barroso A 2005 Ultra-sonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 24:1385-1389. (Pubitemid 41395927)
16. Rosario PW, Tavares Júnior WC, Biscolla RP, Purisch S, Maciel RM 2007 Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metab 51:593-600.
17. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5cm in diameter: study of 299 cases. J Clin Endocrinol Metab 89:3713-3720. (Pubitemid 39071462)
18. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY 2002 Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin En-docrinol (Oxf) 57:215-221. (Pubitemid 34989098)
19. Seo JH, Lee SW, Ahn BC, Lee J 2010 Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG pet/ct. Clin Endocrinol (Oxf) 72:558-563.
20. Vincze B, Sinkovics I, Keresztes S, Gergye M, Boér A, Re-menár E, Péter I, Szentirmay Z, Kremmer T, Kásler M 2004 Clinical significance of serum thyroglobulin and antithyro-globulin antibody in differentiated thyroid cancer after thyroid ablation. Magy Onkol 48:27-34.
21. 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 20:547-552. (Pubitemid 44818585)
22. Aras G, Gültekin SS, Küçük NO 2008 The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer. Nucl Med Commun 29:880-884.
23. Schlumberger MJ 1999 Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22(11 Suppl):3-7.
24. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum anti-thyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93:4683-4689.